-+ 0.00%
-+ 0.00%
-+ 0.00%

Autolus says FDA grants RMAT designation for obe-cel in lupus, lupus nephritis

PUBT·09/09/2026 11:05:44
Listen to the news
Autolus says FDA grants RMAT designation for obe-cel in lupus, lupus nephritis
  • FDA granted RMAT designation for Autolus’ obe-cel in systemic lupus erythematosus, including lupus nephritis.
  • Designation supports accelerated development, regulatory review for the cell therapy in serious disease.
  • Pivotal Phase 2 LUMINA study in refractory lupus nephritis continues enrolling; data expected in 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090700PRIMZONEFULLFEED9823217) on September 09, 2026, and is solely responsible for the information contained therein.